Suppr超能文献

心脏导管插入术和心脏手术期间的鱼精蛋白过敏反应:服用鱼精蛋白胰岛素制剂患者的风险

Protamine allergy reactions during cardiac catheterization and cardiac surgery: risk in patients taking protamine-insulin preparations.

作者信息

Vincent G M, Janowski M, Menlove R

机构信息

Department of Medicine, LDS Hospital, University of Utah School of Medicine, Salt Lake City 84143.

出版信息

Cathet Cardiovasc Diagn. 1991 Jul;23(3):164-8. doi: 10.1002/ccd.1810230303.

Abstract

Protamine insulin use may immunologically sensitize patients to protamine, leading to anaphylactoid reactions upon subsequent exposure to protamine sulfate during cardiac catheterization or cardiovascular surgery. The risk of such reactions in protamine insulin-dependent patients is uncertain. One catheterization study reported a 50-fold greater risk while a second showed no increased risk! To clarify the risk, the records of 7,750 cardiac catheterization procedures between 1984 and 1987 were analyzed for presence of NPH or PZI insulin use, protamine administration, and any complications or adverse reactions. Protamine was administered in 3,341/7,750 procedures (43%), including 171 in diabetics receiving NPH insulin. Adverse reactions to protamine occurred in 2/3, 170 noninsulin patients, 0.06%, and adverse reactions due to probable NPH insulin sensitization occurred in 1/171, 0.6%, of NPH diabetics, p = .034. Meta-analysis of risk showed an odds ratio of 7.96 for the NPH diabetic patients, and combining these results with the other large series in the literature (269 NPH diabetics total) showed an odds ratio of 4.19 compared to a non-NPH insulin group. Meta-analysis of the surgical literature showed the risk in surgical patients to be 2.1% in NPH patients versus 0.12% with no NPH, with an odds ratio of 15.52. The greater incidence in surgical patients may be due to protamine sensitization at prior catheterization and to the larger dose of protamine administered to surgical patients.

摘要

使用精蛋白胰岛素可能会使患者在免疫上对精蛋白敏感,导致在随后的心导管插入术或心血管手术期间接触硫酸鱼精蛋白时发生类过敏反应。依赖精蛋白胰岛素的患者发生此类反应的风险尚不确定。一项心导管插入术研究报告称风险高50倍,而另一项研究则显示风险并未增加!为了明确风险,对1984年至1987年间7750例心导管插入术的记录进行了分析,以确定是否使用了中性鱼精蛋白锌胰岛素(NPH)或鱼精蛋白锌胰岛素(PZI)、是否给予了鱼精蛋白以及是否有任何并发症或不良反应。在7750例手术中有3341例(43%)给予了鱼精蛋白,其中包括171例接受NPH胰岛素治疗的糖尿病患者。2/3170例非胰岛素患者发生了对鱼精蛋白的不良反应,发生率为0.06%,1/171例(0.6%)NPH糖尿病患者发生了可能因NPH胰岛素致敏引起的不良反应,p = 0.034。风险的荟萃分析显示,NPH糖尿病患者的优势比为7.96,将这些结果与文献中的其他大型系列研究(总共269例NPH糖尿病患者)相结合,与非NPH胰岛素组相比,优势比为4.19。手术文献的荟萃分析显示,手术患者中NPH患者的风险为2.1%,而非NPH患者为0.12%,优势比为15.52。手术患者中发生率较高可能是由于先前心导管插入术时鱼精蛋白致敏以及手术患者给予的鱼精蛋白剂量较大。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验